Clinical trial
Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer
NCT00217477 · Roswell Park Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00217477 |
|---|---|
| Title | Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer |
| Official title | An Open Label, Dose Escalation Study of Paricalcitol (Zemplar™) [19-NOR-1 ALPHA, 25-(OH) D] in Combination With Gemcitabine [2', 2' -Difluorodeoxycytidine] in Patients With Advanced Malignancies |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Collaborators | Abbott Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | gemcitabine hydrochloride, paricalcitol |
| Enrollment | 34 |
| Start date | Aug 1, 2004 |
| Primary completion | May 1, 2013 |
| Completion | Sep 1, 2014 |
| First posted | Sep 22, 2005 |
| Last update posted | Dec 9, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: